U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07161778) titled 'A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer' on Oct. 21, 2014.
Brief Summary: When metastatic prostate cancer becomes unresponsive to hormone therapy, it is known as castration resistant prostate cancer, treatment options are limited and response to this treatment can be short.
The standard treatment for this type of cancer (hydrocortisone or dexamethasone) gives an average response time of 4 months. After this chemotherapy would be considered. In this patient population the majority of men are aged over 70, so giving chemotherapy with its associated toxicities; can reduce the quality of li...